Although patients who obtained a 50–64% reduction in MMD during CGRP (pathway) mAb‐treatment reported a significant increase in MMD, MHD, and AMD during the mandatory treatment break, surprisingly, patient subgroups who benefitted even more from CGRP (pathway) mAb‐treatment (≥ 75% response rate) reported no significant change in MMD, MHD, and AMD. Here, CALCA is linked to age-related macular degeneration.